Venrock-backed startup Corvidia snags $60M round to develop ex-AstraZeneca drug
A new startup founded by a handful of ex-AstraZeneca folks has hauled in a $60 million Series B round led by Venrock to push forward its Phase II trial for advanced kidney disease.
The company was co-founded in 2016 by Michael Davidson, the former CMO of New Jersey-based Omthera, which sold to AstraZeneca for $443 million back in 2013. Davidson and a couple of AstraZeneca scientists launched Corvidia Theapeutics with a drug program it in-licensed from the pharma giant.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
